+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The use of viral load as a surrogate marker in predicting disease progression for patients with early invasive cervical cancer with integrated human papillomavirus type 16

The use of viral load as a surrogate marker in predicting disease progression for patients with early invasive cervical cancer with integrated human papillomavirus type 16

American Journal of Obstetrics and Gynecology 201(1): 79.E1-7

The purpose of this study was to assess the effectiveness of the use of human papillomavirus type 16 (HPV16) physical status and viral load in combination to predict clinical outcome during cervical development. A follow-up study was monitored in association with HPV integration and viral load in 121 cervical samples with the use of multiplex quantitative polymerase chain reaction. A significant increase of viral load was found earlier from preinvasive to invasive groups compared with normal groups, except with clinical staging and clinical outcome. High occurrence of integrated HPV16 was observed in preinvasive (27/44 samples) and invasive cervical carcinoma (40/68 samples). Cervical progression was observed significantly in most preinvasive (18/27 samples) and invasive cases (25/40 samples) that were infected with integrated HPV. Integrated HPV16 with significant viral load can be used as a predictive marker for tumor progression in the early stage of invasive cervical carcinoma. Integrated HPV16 in combination with viral load is a predictive indicator for tumor progression in early invasive stage but not in preinvasive and advanced invasive stage.

(PDF emailed within 0-6 h: $19.90)

Accession: 056529798

Download citation: RISBibTeXText

PMID: 19446285

DOI: 10.1016/j.ajog.2009.03.013

Related references

Human papillomavirus viral load: a possible marker for cervical disease in HIV-infected women. Journal of Antimicrobial ChemoTherapy 57(5): 810-814, 2006

Analysis of human papillomavirus type 18 load and integration status from low-grade cervical lesion to invasive cervical cancer. Journal of Clinical Microbiology 47(2): 287-293, 2008

Changes in type-specific human papillomavirus load predict progression to cervical cancer. Journal of Cellular and Molecular Medicine 16(12): 3096-3104, 2014

Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer. Cancer Epidemiology, Biomarkers & Prevention 14(5): 1311-1314, 2005

Human papillomavirus type 16 viral load in relation to HIV infection, cervical neoplasia and cancer in Senegal. Cancer Epidemiology 38(4): 369-375, 2015

Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiology, Biomarkers & Prevention 18(1): 113-120, 2009

The significance of physical status of human papillomavirus type 16 for predicting the effectiveness of invasive cervical cancer treatment. Voprosy Onkologii 59(6): 756-760, 2014

Prognostic significance of human papillomavirus viral load in correlation with different therapeutic modalities in cervical cancer patients. Pathology, Research and Practice 212(9): 804-810, 2016

Human papillomavirus 16 DNA in cervical cancers and in lymph nodes of cervical cancer patients: a diagnostic marker for early metastases?. International Journal of Cancer 43(1): 41-44, 1989

High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clinical Cancer Research 13(1): 132-138, 2007

Detection of integrated papillomavirus oncogene transcripts as marker for advanced cervical dysplasia and invasive cancer. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1025, July, 2003

Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecologic Oncology 102(1): 54-60, 2006

Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. New England Journal of Medicine 337(18): 1267-1274, 1997

Association between viral loads of different oncogenic human papillomavirus types and the degree of cervical lesions in the progression of cervical Cancer. Clinica Chimica Acta; International Journal of Clinical Chemistry: -, 2018

Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 360(9328): 228-229, 2002